Bleeding Disorder Testing Market

Market Overview:

The global bleeding disorder testing market size reached US$ 94.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 175.0 Million by 2032, exhibiting a growth rate (CAGR) of 7.06% during 2024-2032. The rising prevalence of bleeding disorders, the increasing number of traumas and surgeries, extensive research and development (R&D) activities, and the implementation of supportive government policies are some of the major factors propelling the market.

Bleeding disorder testing refers to a diagnostic process used to identify and evaluate conditions characterized by abnormal bleeding tendencies. It includes complete blood count (CBC), coagulation profile, platelet function tests, factor assays, genetic testing, and Von Willebrand factor (VWF) assays. Blood disorder testing is widely used to identify bleeding disorders, guide appropriate treatments, assess bleeding risk, monitor treatment efficacy, and provide preoperative evaluation. It is a highly effective, safe, and accurate testing that provides precise diagnosis, prevents complications, enables early intervention, and improves clinical outcomes.

The rising awareness regarding early diagnosis and treatment of bleeding disorders to prevent future complications, increase treatment success, and reduce healthcare expenditure is positively influencing the market growth. Additionally, the easy accessibility of bleeding disorder testing due to the rapid improvement in the healthcare infrastructure is catalyzing the market growth. Furthermore, the growing demand for point-of-care testing (POCT) to offer quick results and enhance patient convenience is strengthening the market growth. Apart from this, the implementation of supportive government policies to spread awareness regarding bleeding disorders, reimburse patients for testing, and provide access to high-quality treatment facilities is contributing to the market growth. Other factors, including the rapid expansion of the healthcare industry, increasing investments in the development of advanced testing methods, and the rising geriatric population, are anticipated to drive the market growth.

Bleeding Disorder Testing Market Trends/Drivers:

The rising prevalence of bleeding disorders across the globe

Bleeding disorder testing is a highly efficient technique used for diagnosing and determining the severity of hemophilia A and B, which aids healthcare professionals in monitoring treatment effectiveness and adjusting factor replacement therapy dosages. Furthermore, it assists in the identification, treatment, and monitoring of Von Willebrand disease (VWD) by measuring VWD antigen levels, activity, and factor VIII levels. Moreover, bleeding disorder testing is extensively used to identify defects in platelet adhesion, aggregation, secretion, and receptor function, which aids in the diagnosis and management of platelet function disorders (PFDs). Additionally, it is used in the treatment of acquired hemophilia to monitor the inhibitor levels during the immune tolerance induction therapy. Apart from this, bleeding disorder testing is widely used in the accurate identification and diagnosis of rare bleeding disorders, including the deficiencies of specific clotting factors, such as factors II, V, VII, X, XI, and XIII.

The increasing number of traumas and surgeries

Bleeding disorder testing is widely used in preoperative screening to identify patients at risk of excessive bleeding during and after surgery. It aids in assessing the patient's overall coagulation profile, detects underlying bleeding disorders, and guides the selection of appropriate surgical interventions and perioperative management strategies. Furthermore, bleeding disorder testing assists in determining the most suitable hemostatic management strategies for trauma and surgical patients. Apart from this, it aids healthcare professionals in ensuring the safe and appropriate selection of blood products during blood transfusion processes. Moreover, bleeding disorder testing is extensively used in anticoagulant therapy to monitor anticoagulation effects in trauma patients and ensure appropriate hemostatic management. In addition to this, it plays a crucial role in managing postoperative bleeding complications.

Extensive research and development (R&D) activities

The introduction of next-generation sequencing, which allows simultaneous analysis of multiple genes associated with various bleeding disorders, thus facilitating precise diagnosis and personalized treatment planning, is providing a thrust to the market growth. Furthermore, the recent development of point-of-care testing (POCT) devices that provide on-site testing capabilities and deliver quick results, which enables immediate treatment decisions, is supporting the market growth. In addition to this, the utilization of artificial intelligence (AI) to analyze large data sets of testing results, identify patterns, and predict patient outcomes is positively influencing the market growth. Additionally, the adoption of digital microfluidics technology, which accelerates clotting assays, reduces sample volumes, and improves testing efficiency in bleeding disorder diagnostics, is propelling the market growth.

Bleeding Disorder Testing Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global bleeding disorder testing market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product type, indication, and end user.

Breakup by Product Type:

• Reagents and Consumables
• Instruments
   

Reagents and consumables dominate the market.

The report has provided a detailed breakup and analysis of the bleeding disorder testing market based on product type. This includes reagents and consumables and instruments. According to the report, reagents and consumables represented the largest market segment.

Reagents and consumables hold the majority market share as they play a vital role in preparing samples, running assays, and obtaining accurate test results. Furthermore, the growing demand for repeated testing to ensure accurate and reliable results is propelling the market growth. Additionally, the recent development of specialized and customized reagents and consumables that are tailored to specific testing methodologies and assays is contributing to the market growth. Apart from this, the widespread product utilization in laboratories, hospitals, and diagnostic centers to perform large-scale testing owing to the increasing prevalence of bleeding disorders is boosting the market growth. Moreover, the rapid expansion of test menus and the introduction of new assay types are acting as another growth-inducing factor.

Breakup by Indication:

• Hemophilia A
• Hemophilia B
• Von Willebrand Disease
• Idiopathic Thrombocytopenic Purpura
• Others
   

Hemophilia A accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the bleeding disorder testing market based on the indication. This includes hemophilia A and hemophilia B, von Willebrand disease, idiopathic thrombocytopenic purpura, and others. According to the report, hemophilia A represented the largest market segment.

Hemophilia A is dominating the bleeding disorder testing market as it is the most common type, which accounts for the majority of hemophilia cases. Apart from this, it is characterized by severe and potentially life-threatening bleeding episodes, which necessitates accurate diagnosis and continuous monitoring to prevent and manage complications. Furthermore, hemophilia A requires a comprehensive diagnostic approach, including coagulation factor assays, genetic testing, and clinical evaluation, which is contributing to the market growth. Additionally, the recent development of advanced testing options, specialized reagents, and consumables specific to this condition is positively influencing the market growth. Moreover, the implementation of supportive government policies to spread awareness regarding hemophilia A and timely testing for effective patient care is strengthening the market growth.

Breakup by End User:

• Hospitals and Clinics
• Diagnostic Centers
• Others
   

Hospitals and clinics represents the largest segment

The report has provided a detailed breakup and analysis of the bleeding disorder testing market based on end user. This includes hospitals and clinics, diagnostic centers, and others. According to the report, hospitals and clinics represented the largest market segment.

Hospitals and clinics are dominating the bleeding disorder market due to the presence of specialized medical professionals, including hematologists and pathologists, who have extensive knowledge and experience in diagnosing and managing bleeding disorders. Furthermore, they have advanced diagnostic facilities equipped with the latest technologies and equipment necessary for comprehensive bleeding disorder testing services under one roof, such as coagulation factor assays, platelet function tests, genetic testing, and von Willebrand factor analysis. Apart from this, hospitals and clinics offer timely results to patients and healthcare providers, which facilitates prompt diagnosis, treatment decisions, and patient management. Additionally, they adhere to stringent quality control measures and standardized protocols, which enhances the trust and credibility of diagnostic centers.

Breakup by Region:

• North America
  • United States
  • Canada
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Latin America 
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

North America exhibits a clear dominance in the market, accounting for the largest bleeding disorder testing market share.

The report has also provided a comprehensive analysis of all the major regional markets, which includes North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represented the largest market segment.

North America is dominating the bleeding disorder testing market owing to the presence of an advanced healthcare infrastructure comprising hospitals, clinics, and diagnostic facilities equipped with state-of-the-art technologies. Additionally, the high prevalence of bleeding disorders, including hemophilia and von Willebrand disease, in the region are acting as another growth-inducing factor. Furthermore, the implementation of supportive government policies to spread awareness, educate the masses, and provide access to high-quality healthcare facilities is positively influencing the market growth. Apart from this, the rising consumer awareness towards testing and early diagnosis of bleeding disorders to prevent future complications and reduce healthcare expenditure is contributing to the market growth. Besides this, the increasing emphasis on technological advancements by regional players to enhance the quality and accessibility of bleeding disorder testing is strengthening the market growth.

Competitive Landscape:

The key players in the bleeding disorder testing market are developing advanced products with enhanced sensitivity, specificity, and efficiency. Along with this, the leading companies are expanding their portfolio by designing new assay kits, reagents, consumables, and diagnostic platforms. Furthermore, the growing strategic partnerships and collaborations between top companies, industry players, research institutions, and healthcare organizations to leverage complementary expertise, access new markets, and develop joint research and development projects is positively influencing the market growth. Moreover, leading companies are establishing new distribution networks and subsidiaries to strengthen their market presence, attract new customers, and increase sales. Apart from this, aggressive marketing and promotional activities by manufacturers through social media, events, and industry conferences to improve brand visibility and create awareness about their products are contributing to the market growth.

The report has provided a comprehensive analysis of the competitive landscape in the global bleeding disorder testing market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Abbott Laboratories
• DiaPharma Group Inc.
• HORIBA Ltd
• HYPHEN BioMed (Sysmex Corporation)
• Precision BioLogic Incorporated
• PreventionGenetics (Exact Sciences Corporation)
• Roche Holding AG
• Siemens Healthineers AG (Siemens AG)
• Thermo Fisher Scientific Inc.
• Werfen S.A.

Recent Developments:

• In March 2023, US Food and Drug Administration (FDA) cleared the Abbott Laboratories blood test for traumatic brain injuries (TBI).
• In May 2022, HORIBA Ltd showcased its new generation of hemostasis analyzers and ready-to-use reagents for hemostasis at the International Society on Thrombosis and Haemostasis (ISTH) 2022.
• In January 2023, Precision BioLogic Incorporated announced the FDA clearance and launch of its new hemophilia-related diagnostic products in the United States.

Bleeding disorder testing Market Report Scope:

Key Questions Answered in This Report:

• How has the global bleeding disorder testing market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global bleeding disorder testing market?
• What is the impact of each driver, restraint, and opportunity on the global bleeding disorder testing market?
• What are the key regional markets?
• Which countries represent the most attractive bleeding disorder testing market?
• What is the breakup of the market based on the product type?
• Which is the most attractive product type in the bleeding disorder testing market?
• What is the breakup of the market based on the indication?
• Which is the most attractive indication in the bleeding disorder testing market?
• What is the breakup of the market based on the end user?
• Which is the most attractive end user in the bleeding disorder testing market?
• What is the competitive structure of the global bleeding disorder testing market?
• Who are the key players/companies in the global bleeding disorder testing market?

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the bleeding disorder testing market from 2018-2032.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global bleeding disorder testing market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the bleeding disorder testing industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.